Advertisement
Canada markets closed

  • S&P/TSX

    22,116.69
    -152.43 (-0.68%)
     

  • S&P 500

    5,283.40
    +5.89 (+0.11%)
     

  • DOW

    38,571.03
    -115.29 (-0.30%)
     

  • CAD/USD

    0.7333
    -0.0006 (-0.09%)
     

  • CRUDE OIL

    73.70
    -0.52 (-0.70%)
     

  • Bitcoin CAD

    94,468.19
    +1,312.27 (+1.41%)
     

  • CMC Crypto 200

    1,448.43
    -19.50 (-1.33%)
     

  • GOLD FUTURES

    2,365.90
    -3.40 (-0.14%)
     

  • RUSSELL 2000

    2,059.68
    -10.44 (-0.50%)
     

  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     

  • NASDAQ futures

    18,656.25
    +10.00 (+0.05%)
     

  • VOLATILITY

    13.11
    +0.19 (+1.47%)
     

  • FTSE

    8,262.75
    -12.63 (-0.15%)
     

  • NIKKEI 225

    38,749.25
    -173.78 (-0.45%)
     

  • CAD/EUR

    0.6720
    -0.0007 (-0.10%)
     

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV

PR Newswire
·1 min read

SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)
BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:


Investors                                                                                             

Media

Traci McCarty                                                                                     

Marni Kottle

BioMarin Pharmaceutical Inc.                                                             

BioMarin Pharmaceutical Inc.

(415) 455-7558                                                                                       

(650) 374-2803

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-bofa-securities-2024-health-care-conference-on-wednesday-may-15-at-1000am-pt--100pm-et-in-las-vegas-nv-302139003.html

SOURCE BioMarin Pharmaceutical Inc.